Q-omics provides the consensus-scored SH2D7 profile across patient tissues and cancer cell-line models. SH2D7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SH2D7 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SH2D7 RNA expression shows 17,428 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, COAD, and TGCT as cancer lineages where SH2D7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH2D7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH2D7 survival associations across molecular data types. SH2D7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH2D7 RNA expression–survival associations across cancer types. High SH2D7 expression shows unfavorable associations in BRCA, LGG, MESO, OV, LIHC and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for SH2D7 RNA expression.
This table summarizes SH2D7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SH2D7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH2D7 shows lower tumor expression in COAD, READ, BRCA and KIRC and higher tumor expression in KICH and HNSC. The COAD box plot shows higher SH2D7 RNA expression in normal versus tumor tissue (log2 FC = −2.624, t-test p < 0.001).
This table shows molecular features associated with SH2D7 in patient tissues and cancer cell lines. In patient samples, SH2D7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SH2D7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
